(Corrects paragraph 1 to remove reference to 2016)
Dec 16 (Reuters) - Canadian drugmaker Valeant
Pharmaceuticals International Inc VRX.TO cut its revenue and
profit forecasts for 2015.
The company, which is holding its investor day on Wednesday,
said it still expected double-digit sales growth through higher
volumes.